Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
Phase 2
Not yet recruiting
- Conditions
- SLE (Systemic Lupus)CMV
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06971913
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Bejing, China
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast CancerHER2-negative Breast CancerctDNA MonitoringBreast Cancer Early Stage Breast Cancer (Stage 1-3)
- Interventions
- Drug: Taxane-Based Neoadjuvant ChemotherapyDrug: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 393
- Registration Number
- NCT06970912
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.
Not Applicable
Not yet recruiting
- Conditions
- AMLElderly
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 307
- Registration Number
- NCT06946602
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT
Not yet recruiting
- Conditions
- ElderlyGeriatric AssessmentALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 176
- Registration Number
- NCT06946654
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy
Phase 2
Not yet recruiting
- Conditions
- Endometrial CancerAtypical Endometrial Hyperplasia
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT06942377
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Not Applicable
Recruiting
- Conditions
- Non-small Cell Lung CancerMinimal Residual DiseaseAdaptive Treatment
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT06930807
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
Not Applicable
Active, not recruiting
- Conditions
- Multiple Myeloma, Neoplasms
- Interventions
- Drug: Aponermin, pomalidomide, dexamethasone
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 105
- Registration Number
- NCT06924424
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Efficacy and Safety of Laparoscopic Lateral Suspension and Transvaginal Sacrospinous Ligament Fixation in Patients With Pelvic Organ Prolapse
Not Applicable
Recruiting
- Conditions
- Pelvic Organ Prolapse (POP)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT06903988
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation
Not Applicable
Not yet recruiting
- Conditions
- Endometrial CancerMobile ApplicationsWeight Management
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT06901778
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Phase 2
Recruiting
- Conditions
- Systemic Lupus ErythematosusANCA-associated VasculitisInflammatory MyopathySystemic Sclerosis (SSc)IgG4-Related DiseasesAntiphospholipid SyndromeAcquired Thrombotic Thrombocytopenic PurpuraBehcet DiseaseSjogren Syndrome
- Interventions
- Drug: BCMA-CD19 CAR-T therapy
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06794008
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath